Multiple Myeloma, the second most common type of blood cancer after non-Hodgkin lymphoma, is characterized by the presence of malignant plasma cells in the bone marrow. The diagnosis involves identifying these highly abnormal and unstable cells, which proliferate aggressively and spread through the bloodstream and lymph nodes. This results in an overwhelming presence of cancer cells in the bone marrow, outnumbering healthy blood cells and immunoglobulins. Consequently, the body's ability to function normally and fight infections is severely compromised, making timely diagnosis and treatment crucial. Multiple Myeloma can present in various forms, including symptomatic ...
